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ABSTRACT
Objectives: The respiratory pathogen Chlamydia pneumoniae (C. pneumoniae) produces acute
and chronic lung infections and is associated with asthma. Evidence for effectiveness of
antichlamydial antibiotics in asthma is limited. The primary objective of this pilot study was to
investigate the feasibility of performing an asthma clinical trial in practice settings where most
asthma is encountered and managed. The secondary objectives were to investigate (1) whether
azithromycin treatment would affect any asthma outcomes and (2) whether C. pneumoniae
serology would be related to outcomes. This report presents the secondary results.
Design: Randomized, placebo-controlled, blinded (participants, physicians, study personnel,
data analysts), allocation-concealed parallel group clinical trial.
Setting: Community-based health-care settings located in four states and one Canadian
province.
Participants: Adults with stable, persistent asthma.
Interventions: Azithromycin (six weekly doses) or identical matching placebo, plus usual
community care.
Outcome Measures: Juniper Asthma Quality of Life Questionnaire (Juniper AQLQ),
symptom, and medication changes from baseline (pretreatment) to 3 mo posttreatment
(follow-up); C. pneumoniae IgG and IgA antibodies at baseline and follow-up.
Results: Juniper AQLQ improved by 0.25 (95% confidence interval;  0.3, 0.8) units, overall
asthma symptoms improved by 0.68 (0.1, 1.3) units, and rescue inhaler use decreased by 0.59
( 0.5, 1.6) daily administrations in azithromycin-treated compared to placebo-treated
participants. Baseline IgA antibodies were positively associated with worsening overall asthma
symptoms at follow-up (p ¼ 0.04), but IgG was not (p ¼ 0.63). Overall asthma symptom
improvement attributable to azithromycin was 28% in high IgA participants versus 12% in low
IgA participants (p for interaction ¼ 0.27).
Conclusions: Azithromycin did not improve Juniper AQLQ but appeared to improve overall
asthma symptoms. Larger community-based trials of antichlamydial antibiotics for asthma are
warranted.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Chlamydia pneumoniae (C. pneumoniae) is a ubiquitous intra-
cellular human pathogen that is reported to cause approx-
imately 10% of community-acquired pneumonia and 5% of
acute bronchitis [1]. Chlamydial infections are characterized
by persistence and immunopathologic damage to host target
tissues, including the lung. C. pneumoniae infection has been
associated with acute asthmatic bronchitis [2,3], bronchial
hyperreactivity [4,5], new-onset asthma [6], chronic asthma
[3,5], ‘‘infectious asthma’’ (asthma that ﬁrst became symp-
tomatic after an acute lower respiratory tract illness) [7], and
asthma severity [8–10].
Chlamydia–asthma associations raise the question whether
antibiotic treatment can improve asthma long term, but
clinical trial evidence for persisting antichlamydial antibiotic
effects on asthma is limited. An open-label before-after trial
in 48 adults with stable, persistent asthma reported that over
half of participants who were treated with 3–9 wk of
antibiotics, consisting mostly of azithromycin, had major
lasting clinical improvement or complete remission of
asthma symptoms [11]. A preliminary report of a randomized
trial of 10 d of telithromycin (a ketolide antibiotic with
antichlamydial activity) in 278 adults with acute asthma
exacerbations documented signiﬁcant positive effects at the
end of treatment [12] but did not report whether the
improvement persisted.
The primary objectives of our pilot study were to
investigate (1) the feasibility of performing an asthma clinical
trial in practice settings and (2) the utility of an interactive
voice-response (IVR) telephone system to collect asthma
outcome data. The primary feasibility results have been
published elsewhere [13]. In summary, we concluded that
physician recruiting, randomizing, and completing a repre-
sentative sample of adult asthma patients was feasible, but
that utility of IVR in primary care research required further
study, primarily because of underreporting. For example, 39
(87%) of 45 participants attended the follow-up clinical visit,
36 (80%) provided complete quality-of-life data, and 33
(73%) provided adequate asthma symptom and rescue
bronchodilator medication data. The secondary objectives
were to investigate (1) whether azithromycin treatment would
affect any asthma outcome measures and (2) whether C.
pneumoniae serology would be related to outcomes. This
report presents the secondary results.
METHODS
Participants
We performed a community-based, multisite, randomized,
allocation-concealed, blinded (patient, physician, data collec-
tor, data analyst), placebo-controlled trial in 45 adults with
stable, persistent asthma recruited from primary care
practices, an emergency room, and a community-based
asthma research center. Potentially eligible patients were
those aged 18 or older with a diagnosis of current asthma
(variable symptoms of wheeze, chest tightness, cough, or
shortness of breath triggered by a variety of stimuli) that was
persistent, stable, and present for more than 3 mo prior to
enrollment [14]. Stability was assessed during a 2–3 wk run-in
period during which eligible patients remained in the same
severity class (mild, moderate, or severe) and had no acute
exacerbations. Documented objective evidence for reversible
airway obstruction, either spontaneously or after treatment,
was also required prior to randomization, either FEV1 change
of 12% (and  200 mL) [14] or peak expiratory ﬂow rate
change of 25% (and  60 L/min) [15]. Exclusion criteria
included (1) ingestion of any macrolide, tetracycline, or
quinolone in the 6 wk before randomization, (2) macrolide
allergy, (3) any unstable illness or other cause for symptoms,
(4) use of coumadin, anticonvulsants, or digoxin and (5)
pregnancy or lactation. The respective human subjects
committees approved the study, and all participants provided
written informed consent.
Interventions
On the basis of the results of previous open-label treatment
[11], we chose as study medication azithromycin, one 600-mg
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Editorial Commentary
Background: Chlamydia pneumoniae is a common bacterium thought to
be responsible for a substantial proportion of community-acquired
pneumonia and bronchitis infections. There is some observational
evidence associating chronic C. pneumoniae infection with more severe
symptoms in people with asthma. However, there are very little data
from clinical trials determining whether treatment with antibiotics active
against C. pneumoniae has an effect on the control of asthma.
What this trial shows: In this trial, the researchers randomized 45 adults
who were being treated for asthma in primary care to receive either
azithromycin (an antibiotic active against C. pneumoniae) or placebo, in
addition to their usual asthma care. Participants were followed up for 3
mo after completion of treatment, during which time participants
recorded data relating to their overall symptoms and daily activities on a
5-point scale, and use of bronchodilators. At the start of the trial, and at
3-mo follow-up, participants also completed a quality-of-life question-
naire using a validated scale. The primary objective of this trial was to
investigate the feasibility of running an asthma trial in the primary care
setting, and in using IVR telephone systems to collect the outcome data,
reported in [13]. In this paper, the asthma outcomes are reported.
Participants receiving azithromycin did not show a significant improve-
ment in quality of life at 3-mo follow-up as compared to participants
receiving placebo. However, the investigators did see a significant
improvement in the overall symptoms recorded by participants receiving
azithromycin, as compared to placebo.
Strengths and limitations: The randomization methods in the trial were
appropriate, as was the choice of placebo as a comparison for
azithromycin. However, the number of participants in the trial was small,
and it is likely that many more participants would need to be recruited to
conclusively demonstrate or disprove an effect of azithromycin on
asthma-related quality of life. Further, the trial used three different
measures for asthma outcomes: (1) the quality-of-life questionnaire, (2)
measurement of symptoms and daily activities on a 5-point scale, and (3)
bronchodilator use. Only the quality-of-life questionnaire is validated,
making it difficult to compare the results with those of other asthma
trials.
Contribution to the evidence: This trial provides suggestive evidence
that azithromycin may have benefits in the treatment of asthma, but
should not on its own lead to a change in practice. The study provides a
good basis for a larger randomized trial of such treatments, which would
need to assess reliably the effect of these drugs not only on symptoms
but also on quality of life. Information gained from this trial would help
to design several aspects of future studies, e.g., their size, follow-up
duration, and suitable outcome measures.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.tablet daily for 3 consecutive days, followed by 600 mg weekly
for an additional 5 wk (total dose 4,800 mg) or identical
placebo tablets. All patients continued to receive usual care
for asthma from their primary physician, who was blinded to
treatment allocation.
Objectives
The secondary results reported here are (1) azithromycin
effects on asthma-speciﬁc quality of life (Juniper AQLQ),
asthma symptoms, and rescue medication use, and (2)
relationships of C. pneumoniae antibodies with these outcomes,
and whether antibody levels were affected by treatment.
Because this was a pilot study, we speciﬁed no primary asthma
outcome.
Asthma Clinical Outcomes
Participants completed the Juniper Asthma Quality of Life
Questionnaire (Juniper AQLQ) [16] at baseline (pretreat-
ment) and follow-up (3 mo after completion of treatment).
Weekly throughout the study, patients were asked to record
their symptoms, impairment in daily activities, and rescue
bronchodilator use for the preceding 24-h period. Symptom
categories were overall asthma symptoms, cough, wheeze,
shortness of breath, and sleep disturbance due to asthma.
Daily activity categories were impairment in work, house-
work, sports, and keeping appointments. Symptoms and
activities were recorded using a 5-point scale (0 ¼ none, no
impairment; 1¼mild; 2¼moderate; 3¼severe; 4¼worst ever,
could not perform). Rescue bronchodilator use was recorded
as the number of episodes of use, not the total number of
puffs. Juniper AQLQ and weekly diary data were reported by
IVR, which did not accept incomplete reports.
Serological Methods
Plasma samples were obtained at baseline and follow-up,
frozen at  70 8C, and tested together in one batch. The
serological ELISA testing was performed using a modiﬁcation
of our previously described method [17]. Brieﬂy, Immunolon
2 plates (Dynex Technologies, Chantilly, Virginia, United
States) were coated with 0.5 lg (based on protein concen-
tration) of lysed C. pneumoniae AR39 elementary bodies in PBS
for 48 h at 4 8C. After this period, plates were washed three
times, and blocked for 90 min at 37 8C with PBS/3%
ovalbumin (grade II)/0.1% Tween 20. Plates were then washed
three times and incubated with triplicate samples of each
patient’s sera. For IgG measurement, sera were diluted 1:200
in PBS/0.1% ovalbumin (grade V)/0.05% Tween 20 and
incubated for 1 h at 37 8C. For IgA measurement, sera were
ﬁrst diluted to 1:10 in GullSORB (Meridian Diagnostics Inc,
Cincinnati, Ohio, United States), a reagent used for IgG
antibody removal, to prevent interference. The ﬁnal dilution
of sera added to plates for IgA measurement was 1:50, and
sera were incubated overnight at 4 8C [18]. Following
incubation of sera, plates were washed three times, incubated
with alkaline phosphatase-conjugated goat antihuman IgG or
IgA (Jackson Immunoresearch Laboratories, West Grove,
Pennsylvania, United States) for 30 min at 37 8C, and mixed
with the substrate, p-nitrophenylphosphate (SigmaFAST
tablets; Sigma Chemical Company, St. Louis, Missouri, United
States). Absorbance was read as optical density (OD) at 405
nm. The OD value of a PBS-coated well that had no antigen
(antigen-blank) was subtracted from the values for all test
wells. Triplicate test OD values were averaged and reported
for each patient. Laboratory personnel performing the ELISA
test were blinded to clinical information on the patients. IgA
measurements on the same samples tested on different days
were highly correlated (R ¼ 0.993, p , 0.0001, coefﬁcient of
variation ,1%).
Sample Size
Because no existing information on which to base sample size
calculations was available, sample size was determined by
available funding. We did not expect to observe any statisti-
cally signiﬁcant treatment effects or serological associations.
Randomization–Sequence Generation
At randomization, participants meeting ﬁnal eligibility
criteria were allocated to study medication bottles that were
coded centrally using a computerized 1:1 (azithromycin:pla-
cebo) allocation ratio blocked by site. Block size was n ¼ 6.
Randomization–Allocation Concealment
Study physicians, research staff, participants, and data
analysts were unaware of allocation due to central random-
ization and coding. Emergency unblinding envelopes were
available, but study sites did not report opening any of them.
Randomization–Implementation
An independent statistician, who had no further contact with
study conduct, generated the randomization sequences. Bulk
study medication tablets were bottled, labeled, and distrib-
uted by an independent pharmaceutical service that had no
further role in study conduct.
Statistical Methods
We employed the ‘‘intention to treat’’ principle. We did not
impute values for missing data. We coded asthma outcomes
so that positive values indicate improvement and negative
values indicate worsening. For each subject, asthma outcome
changes (change scores) were calculated as the absolute
(arithmetic) difference between pre- and posttreatment
values. For Juniper AQLQ, the change score was the differ-
ence between the baseline and follow-up values. For
symptoms, activities, and bronchodilator use, the change
score was the difference between (1) the mean of the ﬁrst
three weekly baseline values and (2) the mean of the last one
to three available follow-up values obtained for study months
5 and 6. We also examined all available overall asthma
symptom data aggregated by month and treatment group,
and used linear regression to test for differences between
azithromycin and placebo groups. We compared binary
categorical variables using the Fisher exact test. We analyzed
continuous, normally distributed outcomes using analysis of
variance and controlled for subject characteristics using
analysis of covariance. We performed a log transformation of
OD prior to analysis. We performed Pearson correlation to
examine relationships between continuous variables (e.g.,
between different asthma outcome scales and between pre-
and posttreatment OD values) and linear regression to test
for signiﬁcance of the correlations. We calculated percentage
changes in asthma symptom scores by dividing the appro-
priate raw change score by 5, the number of scale categories.
After determining that IgA OD was signiﬁcantly associated
with overall asthma symptom changes, we examined IgG and
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Azithromycin, Asthma, and C. pneumoniaeIgA levels as binary variables (low versus high antibody levels).
Because this was a pilot study, no previous criteria were
available. Therefore, cutoff values were determined a priori
(before analysis) by inspection and deﬁned as follows: high
IgG was deﬁned as an OD above the mean (1.18 OD units);
high IgA was deﬁned as an optical density greater than 0.5. In
these analyses, we controlled for various baseline character-
istics (including treatment allocation, with and without a
treatment-antibody interaction term) as speciﬁed in each
result. We report two-sided p-values ,0.05 as signiﬁcant.
DataDeskt version 6 for Macintosh (DataDescription, Inc.,
Ithaca, New York, United States) was used to perform
statistical calculations.
RESULTS
Participant Flow
We recruited participants between September 1999 and
December 2001. Forty-ﬁve participants meeting ﬁnal eligi-
bility criteria were randomized (Figure 1).
Baseline Data
Most enrollees had mild to moderate persistent asthma, less
than half reported an asthma exacerbation within the 2 y
prior to enrollment, and none were oral steroid–dependent.
The median duration of asthma symptoms prior to random-
ization was 14.5 y, and 44% reported that their initial asthma
symptoms began after an acute respiratory illness, the so-
called ‘‘infectious asthma’’ syndrome [19]. With the exception
of sex distribution, the randomized groups were well bal-
anced on baseline characteristics (Table 1).
Study medication adherence was complete except for one
azithromycin subject who reported taking only four of six
weekly doses. During usual care, two azithromycin and three
placebo participants received standard (7–10 d) courses of
antibiotics, only one of which had antichlamydial activity.
One azithromycin and two placebo participants were
prescribed increased doses of anti-inﬂammatory controller
medication. Five azithromycin and two placebo participants
reported mild/moderate gastrointestinal side effects. A single
serious adverse event was reported: one subject allocated
placebo died of asthma-related causes.
Figure 1. Study Flowchart
DOI: 10.1371/journal.pctr.0010011.g001
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Three weeks after treatment began, 40 (89%) of 45
randomized participants provided information about results
of blinding. Five of 20 participants allocated to azithromycin
and four of 20 allocated to placebo guessed they were taking
azithromycin, seven in the azithromycin group and eight in
the placebo group guessed they were taking placebo, and
seven and eight, respectively, indicated that they were not
sure whether they were taking azithromycin or placebo (p ¼
0.9, chi-square test).
Outcomes and Estimation
Asthma outcomes. Table 2 presents results for asthma quality
of life (Juniper AQLQ), symptoms, daily function, and
bronchodilator use. Juniper AQLQ improved by þ0.25 units
( 0.35, 0.84), and bronchodilator use episodes improved by
þ0.59 ( 0.47, 1.64) daily administrations. Differences favored
azithromycin for all asthma symptom and activity outcomes
except work ( 0.02 units). Overall asthma symptoms im-
proved in the azithromycin group (þ0.55) and worsened in
the placebo group ( 0.13). The effect size (þ0.68; 0.05, 1.29) in
favor of azithromycin was statistically signiﬁcant (p ¼ 0.04)
and remained signiﬁcant (p ¼ 0.004) after controlling for
antibody level, age, sex, smoking, skin test status, infectious
onset, age of asthma onset, asthma severity, and change in
controller medication use (mostly inhaled corticosteroids).
Figure 2 presents overall asthma symptom patterns by study
month according to treatment allocation. Maximum overall
symptom improvement in the azithromycin group appeared
by 3 mo, remained stable through 6 mo, and was signiﬁcantly
(p¼0.04) different from placebo by linear regression analysis.
Neither Juniper AQLQ nor the Juniper AQLQ symptom
subscale change scores correlated with overall asthma
symptom change scores (r ¼ 0.19, p ¼ 0.31; r ¼ 0.16, p ¼ 0.38,
respectively) or with bronchodilator change scores (r¼0.27, p
¼ 0.14; r ¼ 0.31, p ¼ .08). Overall asthma symptom change
scores were, however, signiﬁcantly correlated with broncho-
dilator changes (r ¼ 0.55, p , 0.001).
Serological results. Baseline serological samples were
available for 43 (96%) participants. Because treatment was
signiﬁcantly related to overall asthma symptoms (see ‘‘Asthma
outcomes’’ section above) serological analyses were con-
.......................................................................................................................................................................................
Table 1. Baseline Patient Characteristics
Characteristic Subgroup Azithromycin (n ¼ 24) Placebo (n ¼ 21)
Age: mean (SD) 50 (14) 45 (12)
Gender: Male, No. (%) 8 (33) 14 (67)
Smoking: No. (%) Never 15 (63) 13 (62)
Ex-smoker 7 (29) 6 (29)
Current 2 (8) 2 (10)
Race/Ethnicity: No. (%) White 17 (71) 17 (81)
Black 2 (8) 0 (0)
Hispanic 2 (8) 3 (14)
Other 3 (13) 1 (5)
Education: No. (%) ,High school 3 (13) 2 (10)
High school 15 (63) 13 (62)
.High school 6 (25) 6 (29)
Occupation: No. (%) Employed 19 (79) 18 (86)
Homemaker 1 (4) 0 (0)
Retired 2 (8) 2 (10)
Student 1 (4) 0 (0)
Unemployed 1 (4) 1 (5)
Skin testing: No. (%) Negative 1 (4) 1 (5)
Positive 8 (33) 11 (52)
Never tested 15 (63) 9 (43)
Asthma symptom severity
a: No. (%) Mild 11 (46) 13 (62)
Moderate 12 (50) 8 (38)
Severe 1 (4) 0 (0)
Asthma FEV1 severity
a: No. (%) Mild 11 (46) 12 (57)
Moderate 8 (33) 6 (29)
Severe 2 (8) 1 (5)
Not recorded 3 (13) 2 (10)
Exacerbation within 2 y of enrollment: No. (%) Prednisone burst(s) 8 (33) 10 (48)
Unscheduled visit for worsening asthma 10 (42) 6 (29)
Hospitalization for asthma 1 (4) 2 (10)
Any of the above 11 (46) 10 (48)
Age at first asthma symptoms, y: mean (SD) 30 (22) 27 (15)
Asthma duration, y: mean (SD) 20 (18) 19 (15)
First asthma symptoms associated with an acute
respiratory illness: No. (%)
Yes 9 (38) 9 (43)
No 12 (50) 11 (52)
Not recorded 3 (13) 1 (5)
Guideline therapy at randomization
b: No. (%) Yes 20 (83) 16 (76)
No 4 (17) 5 (24)
aNational Heart Lung and Blood Institute Expert Panel Guideline definitions (FEV1 was available for 40 [89%] of participants).
bReported use of inhaled corticosteroid and/or leukotriene antagonist.
DOI: 10.1371/journal.pctr.0010011.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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OD, as a continuous variable, was positively and signiﬁcantly
associated (p ¼ 0.04) with overall asthma symptom changes,
i.e., higher serological values predicted worsening asthma at
follow-up. Baseline IgG OD was not associated with symptom
changes (p¼0.63). We then explored antibody levels as binary
variables. An IgG/IgA scatter plot revealed that participants
were distributed among three of the four possible categories
(high IgG/high IgA [n¼11], high IgG/low IgA [n¼10], and low
IgG/low IgA [n ¼ 21]). There were no participants in the low
IgG/high IgA category (Figure 3). High IgA antibody level
category (p¼0.03), but not high IgG (p¼0.34), was associated
.......................................................................................................................................................................................
Table 2. Juniper AQLQ, Asthma Symptoms, Daily Activities, and Rescue Bronchodilator Use: Baseline Values and Changes at 3 Mo
after Finishing Study Medication
Measures Domains Azithromycin Group
a Placebo Group
a Azithromycin versus
Placebo Difference
b
Baseline Change Baseline Change Effect Size
Juniper AQLQ n ¼ 19 n ¼ 17
4.3 (1.0) þ0.59 (0.8) 4.7 (0.7) þ0.34 (1.0) þ0.25 ( 0.35, 0.84)
Asthma symptoms n ¼ 17 n ¼ 16
Overall 1.7 (0.8) þ0.55 (0.7) 1.4 (0.4) –0.13 (0.9) þ0.68 (0.05, 1.29)*
Cough 1.2 (0.6) þ0.49 (0.8) 1.2 (0.7) þ0.18 (0.8) þ0.32 ( 0.24, 0.87)
Wheeze 1.2 (0.7) þ0.18 (0.6) 1.0 (0.7) –0.14 (0.7) þ0.32 ( 0.15, 0.79)
Dyspnea 1.7 (0.9) þ0.55 (0.9) 1.5 (0.8) þ0.16 (0.7) þ0.39 ( 0.12, 0.91)
Sleep 1.3 (1.0) þ0.50 (1.2) 1.7 (1.0) –0.06 (0.7) þ0.56 ( 0.08, 1.20)
Daily activities n ¼ 17 n ¼ 16
Work 1.5 (1.9) þ0.02 (0.5) 1.5 (1.8) þ0.04 (0.8) –0.02 ( 0.46, 0.42)
Housework 2.2 (2.0) þ0.31 (1.0) 1.9 (2.1) –0.02 (0.4) þ0.33 ( 0.06, 0.72)
Sports 1.9 (2.0) þ0.15 (0.6) 2.7 (2.0) þ0.04 (0.6) þ0.11 ( 0.32, 0.53)
Keeping appointments 0.6 (1.1) þ0.42 (1.1) 0.6 (1.7) –0.16 (0.5) þ0.58 (0.00, 1.15)
Rescue bronchodilator use n ¼ 17 n ¼ 16
Number of daily treatment episodes 2.5 (1.9) þ0.43 (1.8) 2.1 (1.5) –0.16 (1.3) þ0.59 ( 0.47, 1.64)
Symptoms and activities: 5-point scales (0 ¼ no symptoms or impairment, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe, 4 ¼ worst ever/could not perform); Juniper AQLQ: 7-point scale; see
Methods section for definitions of how change scores were calculated; (þ) values indicate improvement and (–) values indicate worsening.
aValues presented as mean (SD).
bValues presented as mean (95% confidence interval).
*p ¼ 0.04.
Juniper AQLQ, Juniper Asthma Quality of Life Questionnaire
DOI: 10.1371/journal.pctr.0010011.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Overall Asthma Symptoms in the Azithromycin and Placebo Groups
Months 1 and 2: Baseline and treatment period. Month 3: Completion of treatment. Months 4–6: Posttreatment. Numbers of participants included in each data
point are indicated under the x-axis. Error bars represent 95% confidence intervals for individual data points. Linear regression analysis showed a significant (p¼
0.04) overall difference between azithromycin and placebo group patterns.
DOI: 10.1371/journal.pctr.0010011.g002
www.plosclinicaltrials.org June | 2006 | e11 0006
Azithromycin, Asthma, and C. pneumoniaewith worsening overall asthma symptoms at follow-up. Results
remained signiﬁcant (p ¼ 0.04) when gender was included as
an additional independent variable.
Thirty participants had baseline IgA results and overall
asthma symptom data at follow-up. The overall asthma
symptom effect size favoring azithromycin was 28% (13%,
42%) in high IgA participants (p ¼ 0.003) versus 12% ( 3%,
29%) in low IgA participants (p¼0.14). A treatment-antibody
interaction term was not signiﬁcant (p ¼ 0.27). Placebo-
treated participants with high IgA levels (n ¼ 3) had a
worsening overall asthma symptom score of  1.2 ( 2.0,  0.5)
units. Placebo-treated participants with low IgA levels (n¼11)
had an improvement of þ0.1 ( 1.6, 1.7) units. Azithromycin-
treated participants with high IgA (n ¼ 6) had an improve-
ment of þ0.2 ( 0.8, 1.2) units, and azithromycin-treated
participants with low IgA (n ¼ 10) had improvement of 0.7
( 1.4, 2.8) units. The correlation between baseline and follow-
up IgA antibody ODs was 0.967 (p , 0.0001) and did not differ
by treatment allocation (p ¼ 0.62).
DISCUSSION
Interpretation
Asthma outcomes. We did not ﬁnd signiﬁcant improvements
in Juniper AQLQ resulting from azithromycin treatment. A
post-hoc power calculation (a ¼ 0.05, b ¼ 0.80, pooled SD ¼
0.89) indicated that 400 completed participants would be
needed to detect the difference we found in Juniper AQLQ
(0.25 units). The Juniper AQLQ conﬁdence intervals included
0.5 unit, which is considered the minimum important change
[20]. Detecting this difference, if it existed, would require 100
completed participants. An overall difference of one unit in
Juniper AQLQ is outside the conﬁdence limits of our results,
but might be plausible for participants with more severe
disease than we studied. Larger trials, with longer follow-up
periods and preferably in patients with more severe asthma,
are warranted to determine whether azithromycin can
improve asthma-speciﬁc quality of life and medication use,
as well as asthma symptoms. Ideally, such trials should include
microbiological assessment for atypical infections, with the
caveat that current diagnostic techniques are indirect and
have not been validated for chronic lung infection, or for
microbiologic eradication.
Neither the Juniper AQLQ nor the Juniper AQLQ
symptom subscale correlated signiﬁcantly with overall asthma
symptom changes or with bronchodilator changes in our
study, whereas overall asthma symptom changes and bron-
chodilator use changes were signiﬁcantly correlated with each
other. The ﬁndings for the Juniper AQLQ are consistent with
the results of factor analysis of asthma outcome data from
three asthma clinical trials [21]. That analysis found that
Juniper AQLQ factored independently from symptoms and
medication use, and that symptoms and medication use
factored together. In our study, the Juniper AQLQ symptom
subscale did not correlate with either the overall asthma
symptom or bronchodilator measures. Evidence favors the
concept that asthma outcomes occupy separate domains,
although debate surrounds their exact number and descrip-
tion [21,22]. The Juniper AQLQ is designed to capture a 2-wk
look-back interval, whereas our overall asthma symptom and
bronchodilator scores measured the previous 24 h. The lack
of correlation we found between the Juniper AQLQ symptom
subscale changes and the overall asthma symptom changes
suggests that the ‘‘look-back’’ duration may be an important
variable in determining the results of asthma domain factor
analyses.
We found suggestive evidence that adjunctive azithromycin
treatment had persisting beneﬁt on overall asthma symptoms,
as measured by our previously unvalidated 5-point symptom
scale. The overall asthma symptom changes, as measured by
this 5-point scale, correlated signiﬁcantly with patient-
reported bronchodilator use changes, thus providing limited
support for its validity. The apparent improvement in overall
asthma was maximal by the third study month and persisted
until ﬁnal follow-up 3 mo after treatment completion. This
result is consistent with a previous open-label before-after
study in which antibiotic (mainly azithromycin) responders
reported that maximum improvement occurred by the third
study month and persisted after treatment ended [11].
However, these results must be interpreted cautiously since
they were obtained in a pilot study that did not specify a
primary asthma outcome. Nevertheless, these preliminary
results support performing further clinical trials in larger
representative samples of asthma patients followed for longer
time periods.
Serological results. A growing body of evidence from
clinical observations and case-control studies supports an
association of C. pneumoniae infection and asthma [23]. Results
from the study reported here show that C. pneumoniae–speciﬁc
IgA antibodies predict 6-mo asthma prognosis, as measured
by an overall asthma symptom scale. This relationship did not
hold for IgG antibodies. There are no validated serodiagnos-
tic tests for chronic C. pneumoniae lung infection. C. pneumo-
niae–speciﬁc IgA antibodies have been suggested as potential
seroepidemiological markers for chronic infection in asthma
[7] and might be useful in epidemiological and primary care
Figure 3. Scatter Plot of Chlamydia pneumoniae–specific IgG and IgA
Optical Density (OD) Values Obtained on Available Baseline Patient Sera
(n ¼ 42)
Y-axis: IgG OD; X-axis: IgA OD. High IgG was defined by inspection as an OD
above the mean (1.18 OD units). High IgA was defined by inspection as an OD
greater than 0.5.
DOI: 10.1371/journal.pctr.0010011.g003
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asthma studies where direct microbiologic sampling of the
lower airway is impractical. The microimmunoﬂuorescence
(MIF) test is the accepted ‘‘gold standard’’ for C. pneumoniae
serologic testing [24]. Our study employed an ELISA test with
proven excellent reproducibility that we previously validated
against the MIF test [25]. Our scatter plot results (Figure 3)
are also consistent with previous MIF data indicating that
almost all patients with detectable C. pneumoniae–speciﬁc IgA
also had detectable high titers of IgG [26]. OD reproducibility,
validation against, and consistency with previous MIF results
support the use of our ELISA. As part of the ELISA method
for measuring IgA antibodies, we performed overnight
incubation of patient samples with the aim of improving
assay sensitivity, as suggested by the work of others using the
MIF test [18]. Our results furnish further evidence [7] that C.
pneumoniae–speciﬁc IgA may have value as a seroepidemio-
logical tool in primary care–based asthma studies.
Since the half-life of IgA is short (about 1 wk [27]),
persisting levels of IgA may indicate ongoing antigenic
stimulation, e.g., chronic infection. In acute, uncomplicated
genitourinary infection, loss of organism-speciﬁc IgA can
correlate with microbiologic eradication of Chlamydia tracho-
matis [28]. It is well recognized that eradication of chronic
chlamydial infections are problematic, and we were unable to
demonstrate any signiﬁcant decrease in C. pneumoniae–speciﬁc
IgA after 6 wk of treatment with azithromycin. We suggest
measuring IgA antibodies after longer treatment courses.
Symptom improvement attributable to azithromycin was
greater (þ1.4, or 28%) in the high IgA category than in the low
IgA category (þ0.6, or 12%), suggesting that IgA might be
useful in predicting treatment response. A treatment-anti-
body interaction term was not statistically signiﬁcant (p ¼
0.27). Further studies are required to investigate whether
chlamydial biomarkers predict treatment outcome.
Generalizability
We enrolled a representative sample of community-based,
nonreferred adults with mainly mild to moderate persistent
stable asthma. We did not exclude participants on the basis of
smoking or on the basis of an element of coexisting ﬁxed
obstruction, since these characteristics are present in about
half of adult asthma patients in the community [29]. Our
results might not apply to asthma patients with milder
symptoms, or to those with more severe disease (e.g., those
who are steroid-dependent or experiencing frequent exacer-
bations).
Overall Evidence
A recently updated Cochrane Review concluded that there is
insufﬁcient evidence to support or refute the use of macro-
lides in patients with chronic asthma, and that further studies
are needed to deﬁne the potential role of macrolides in
asthmatic patients with chronic atypical infections [30]. Our
trial provides evidence relating to the role of the azalide
macrolide, azithromycin, in the treatment of asthma over a 3-
mo follow-up period. Results for some of our outcome data
(overall asthma symptoms) provide suggestive evidence for a
treatment effect over that period of time. Some clinicians
have prescribed macrolides as adjunctive treatment for
asthma since the 1950s [31], believing that macrolides confer
beneﬁt via direct anti-inﬂammatory mechanisms of action
and/or other nonantibiotic effects [32]. An acknowledged
characteristic of anti-inﬂammatory mechanisms is the re-
quirement for ongoing administration of the anti-inﬂamma-
tory medication to maintain clinical effectiveness [33]. If
macrolides beneﬁt asthma via antibiotic mechanisms of
action, then continued clinical beneﬁts after completion of
treatment could be expected.
Limitations
Limitations of this study include its pilot nature, limited size
and array of outcome measures, and relatively short duration.
Randomization failed to achieve gender balance, but results
remained signiﬁcant after adjusting for gender. The outcome
measures (Juniper AQLQ, symptoms, and bronchodilator use)
primarily reﬂect asthma control in our study population with
mild to moderately severe asthma. We did not assess effects
on asthma exacerbations that are an additional important
outcome. Strengths include the prospective clinical trial
study design, representative sample of community-based
patients, requirement for objective pulmonary function
evidence to support the asthma diagnosis, use of a validated
serologic technique, and analysis of patient-oriented out-
comes. Our results support performance of further studies to
investigate whether asthma is treatable with antibiotics.
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010011.sd001 (50 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010011.sd002 (30 KB DOC).
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